Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Mann, der ein Lithium-Unternehmen im Wert von 1,2 Milliarden Dollar aufgebaut hat, ist zurück...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C6GM | ISIN: FR0014005OJ5 | Ticker-Symbol: N/A
Frankfurt
15.10.24 | 15:29
0,746 Euro
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
ACTICOR BIOTECH SA Chart 1 Jahr

Aktuelle News zur ACTICOR BIOTECH

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ACTICOR BIOTECH Aktie jetzt für 0€ handeln
06.03.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.03.2025723The following instruments on Boerse Frankfurt do have their last trading day on 06.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.03.2025ISIN NameFR0014005OJ5 ACTICOR...
► Artikel lesen
06.03.XFRA CAPITAL ADJUSTMENT INFORMATION - 06.03.2025287Das Instrument 7V7 FR0014005OJ5 ACTICOR BIOTECH EO 1 EQUITY wird cum Kapitalmassnahme gehandelt am 06.03.2025 und ex Kapitalmassnahme am 07.03.2025 The instrument 7V7 FR0014005OJ5 ACTICOR BIOTECH EO...
► Artikel lesen
06.01.Acticor Biotech announces its liquidation proceedings363Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced...
► Artikel lesen
19.12.24Acticor Biotech Announces that the Court Judgment Has Been Postponed Until January 2, 2025353Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced...
► Artikel lesen
10.12.24Acticor Biotech Announces the Filing of a Request for Conversion of Receivership Proceedings Into Liquidation Proceedings434Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced...
► Artikel lesen
10.12.24XFRA 7V7: AUSSETZUNG/SUSPENSION203DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILACTICOR BIOTECH...
► Artikel lesen
06.11.24Acticor Biotech Provides an Update on the Current Receivership Proceedings457Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today...
► Artikel lesen
04.11.24Acticor Biotech Publishes Its Half-year Financial Results for 2024738Acticor Biotech publishes its half-year financial results for 2024 Repositioning of glenzocimab in the treatment of ST-segment elevation myocardial infarction (STEMI) Receivership proceedings:...
► Artikel lesen
16.10.24Acticor Biotech: Extension of the Call for Tenders With a View to a Restructuring Plan or Sale Under the Receivership Procedure393Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today...
► Artikel lesen
14.10.24Acticor Biotech appoints François Guillet as Chief Financial Officer390Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten